July 29, 2019 Rafael G. Amado, M.D. Re: Employment Letter of Agreement (“Agreement”) Dear Dr. Amado, Allogene Therapeutics, Inc. (“Allogene” or the “Company”) is pleased to offer you employment on the following terms and conditions.Restricted Stock Unit Agreement • February 27th, 2020 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A...Collaboration and License Agreement • February 27th, 2020 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Collaboration and License Agreement (the “Agreement”), effective as of November 1, 2019 (the “Effective Date”), is made by and between Allogene Therapeutics, Inc., a Delaware corporation with its principal place of business at 210 East Grand Ave., South San Francisco, CA 94080 (“Allogene”), and Notch Therapeutics Inc., a corporation organized and existing under the laws of Ontario, Canada with registered address at 40 King Street West, Suite 2100, Toronto, Ontario M5H 3C2, Canada (“Notch”). Allogene and Notch are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
